B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.